Oruka Therapeutics Announces New Board Member and Board Transition
Oruka Therapeutics, Inc. (ORKA)
Company Research
Source: GlobeNewswire
MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025. “As we rapidly advance our co-lead programs through development, I’m pleased to announce this board transition at Oruka,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. “Chris’s expertise can bring tremendous value to the company as we advance towards late-stage development and think more concretely about how ORKA-001 and -002 could enter the market. We have greatly valued Cameron’s contributions on our Board in helping to shape our strategy and direction in the early stages of building our company, and I would like to p
Show less
Read more
Impact Snapshot
Event Time:
ORKA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORKA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORKA alerts
High impacting Oruka Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ORKA
News
- Oruka Therapeutics Announces New Board Member and Board Transition [Yahoo! Finance]Yahoo! Finance
- Oruka Therapeutics (NASDAQ:ORKA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ORKA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- ORKA-001 Trial Progress and US$180 Million PIPE Financing Might Change The Case For Investing In Oruka Therapeutics (ORKA) [Yahoo! Finance]Yahoo! Finance
- Oruka Therapeutics (NASDAQ:ORKA) had its price target raised by analysts at BTIG Research from $56.00 to $63.00. They now have a "buy" rating on the stock.MarketBeat
- Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $45.00 price target on the stock.MarketBeat
ORKA
Earnings
- 11/12/25 - Beat
ORKA
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 3
- 12/11/25 - Form 8-K
- ORKA's page on the SEC website